Table 5.
Clinical outcome
| Groups a | 0 | 1 | 2 | 3 | 4 | 5 | 6 | Total |
|---|---|---|---|---|---|---|---|---|
| EcoVag® | Lc 4R5 | Lc 23B33 | Lc 21M49 | Lg14869, | Lg 14869 | LaciBios® | ||
| Lg 14869 | Lg 20M39 | Lg 6M9 | Lg 6M9 | Lr 14870, | Lr 14870 | Lr GR-1 | ||
| Lr 14870 | Lj 22B42 | Lj 12B1 | Lc 8R6 | Lg 15527 | Lg 15527 | Lr RC-14 | ||
| Vaginal | Vaginal | Vaginal | Vaginal | Vaginal | Oral | Oral | ||
| n = 9 | n = 12 | n = 10 | n = 10 | n = 9 | n = 4 | n = 9 | n = 63 | |
| 6-month cure (no. and percentage) | 8 (89%) | 9 (75%) | 8 (80%) | 6 (60%) | 6 (67%) | 2 (50%) | 8 (89%) | 47 (74.6%) |
| 12-month cure (no. and percentage) | 7 (78%) | 7 (58%) | 6 (60%) | 7 (70%) | 6 (67%) | 2 (50%) | 6 (67%) | 41 (65.1%) |
| 24-month cure (no. and percentage) | 5 (56%) | 4 (33%) | 6 (60%) | 6 (60%) | 6 (67%) | 2 (50%) | 6 (67%) | 35 (55.6%) |
| Number of patients with new relation during follow up (no. and percentage of all) | 2 (22%) | 4 (33%) | 4 (40%) | 4 (40%) | 2 (22%) | 3 (75%) | 3 (33%) | 22 (34.9%) |
a Each group are given capsules with a mix of two or three Lactobacillus strains: Lg, L. gasseri; Lr, L. rhamnosus; Lc, L. crispatus; Lj, L. jenseneii